Notice of hearing to approve the proposed scheme
Released
Released
Announcement PDF
ASX Announcement
NOTICE OF HEARING TO APPROVE THE PROPOSED SCHEME OF
ARRANGEMENT
21 October 2025, Adelaide, Australia: Mayne Pharma Group Limited ACN 115 832 963 (ASX:MYX)
(Mayne Pharma) refers to its announcement on 16 October 2025 providing an update on Foreign
Investment Review Board (FIRB) approval and its announcement on 15 May 2025 in relation to:
the proposed scheme of arrangement under which it is proposed that Cosette Australia
BidCo Pty Ltd ACN 685 921 126 will acquire 100% of the shares in Mayne Pharma by way of
a scheme of arrangement (Scheme), subject to all applicable conditions being satisfied or
waived (as applicable); and
the orders made by the Supreme Court of New South Wales that Mayne Pharma convene
a meeting of Mayne Pharma shareholders (Scheme Meeting) to consider and vote on the
resolution to approve the Scheme (Scheme Resolution) and approving the distribution of
an explanatory statement providing information about the Scheme and the Notice of
Scheme Meeting (Scheme Booklet) to Mayne Pharma shareholders.
As previously announced to the ASX, Mayne Pharma shareholders approved the Scheme by the
requisite majorities at the Scheme Meeting held on 18 June 2025. The Court hearing to approve
the Scheme (Second Court Hearing) has been rescheduled to take place at 4:30pm (AEDT) on
Monday, 3 November 2025 at the Supreme Court of New South Wales, 184 Phillip St, Sydney NSW
2000.
Mayne Pharma notes the revised date for the Second Court Hearing is after the date by which FIRB
has indicated it expects to make a decision. The Second Court Hearing is still well in advance of
the End Date under the Scheme Implementation Deed, being 20 November 2025.
If FIRB approval is received prior to 31 October 2025, Mayne Pharma may ask the Court to bring
forward the date for the Second Court Hearing promptly following FIRB approval. Mayne Pharma
will keep shareholders updated if such a request is made.
Any Mayne Pharma shareholder has a right to appear and be heard at the Second Court Hearing
and may oppose the approval of the Scheme.
Ifyou wish to opposethe approval oftheScheme, you must filewith theCourt and serveon Mayne
Pharma a notice of appearance in the prescribed form, together with any affidavit on which you
wish to rely at the hearing. The notice of appearance and affidavit must be served on Mayne
Pharma at its address for service at least 1 day before the Second Court Hearing.
Mayne Pharma's address for service is c/- Gilbert+ Tobin, Level 35, Tower Two, International
Towers, 200 Barangaroo Avenue, Sydney NSW 2000 (Attention: Alexandra Whitby).
- ENDS -
Authorised for release to the ASX by the Board Chair
ASX Announcement
Page 2
For further information contact:
Dr Tom Duthy
Investor Relations
+61 402 493 727
ir@maynepharma.com
About Mayne Pharma
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising
novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne
Pharma is a leader in dermatology and women’s health in the United States and also provides
contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-
year track record of innovation and success in developing new oral drug delivery systems. These
technologies have been successfully commercialised in numerous products that continue to be
marketed around theworld. Tolearn more about MaynePharma, pleasevisit maynepharma.com.
Share your feedback
Discover